Can Epstein–Barr virus trigger autoimmune thyroid disease?

Clinical evidence and mechanisms

• Chronic immune activation: Epstein-Barr virus (EBV) establishes lifelong, latent infection in host memory B lymphocytes. Periodic viral lytic reactivation triggers chronic, systemic, and intra-thyroidal immune activation. This persistence drives polyclonal B-cell activation, upregulation of activation-induced cytidine deaminase (AID), and T-cell-mediated bystander activation.
• Inflammatory pathways: EBV components activate pattern recognition receptors, specifically Toll-like receptor 9 (TLR9), prompting a cascade of pro-inflammatory cytokines such as interleukin-17 (IL-17). This persistent inflammatory environment facilitates the breakdown of self-tolerance, contributing to autoimmune thyroid diseases (AITD) like Hashimoto's thyroiditis and Graves' disease.
• Status of molecular mimicry: Although molecular mimicry is a validated mechanism in other EBV-associated autoimmune diseases (such as EBNA-1 cross-reactivity in multiple sclerosis), direct, peptide-level cross-reactivity between EBV antigens and thyroid-specific proteins—including thyroid peroxidase (TPO), thyroglobulin (Tg), and the thyrotropin receptor (TSHR)—has not been definitively demonstrated or experimentally validated in human subjects.

Bottom line

EBV-induced chronic immune activation, bystander inflammation, and polyclonal B-cell stimulation are well-supported contributors to autoimmune thyroid disease pathology. However, molecular mimicry remains a plausible but currently unproven mechanism of EBV-triggered thyroid autoimmunity due to a lack of direct, peptide-level clinical evidence.